These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7795251)

  • 1. Wider benefits of leukodepletion of blood products.
    Copplestone JA; Williamson P; Norfolk DR; Morgenstern GR; Wimperis JZ; Williamson LM
    Blood; 1995 Jul; 86(1):409-10. PubMed ID: 7795251
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
    Philpott N; Mehta J; Treleaven J; Powles R
    Leuk Lymphoma; 1994 Sep; 15(1-2):127-30. PubMed ID: 7858489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
    Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M
    Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
    Stone RM; Mayer RJ
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):47-64. PubMed ID: 8449864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
    Gondo H; Harada M; Miyamoto T; Takenaka K; Tanimoto K; Mizuno S; Fujisaki T; Nagafuji K; Hayashi S; Eto T; Taniguchi S; Akashi K; Harada N; Yamasaki K; Shibuya T; Matsuishi E; Ohno Y; Makino S; Takamatsu Y; Murakawa M; Teshima T; Hirota Y; Okamura T; Kinukawa N; Niho Y
    Bone Marrow Transplant; 1997 Nov; 20(10):821-6. PubMed ID: 9404921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
    Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD).
    Taguchi J; Miyazaki Y; Yoshida S; Fukushima T; Moriuchi Y; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M
    Leukemia; 2000 Nov; 14(11):1861-6. PubMed ID: 11069020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic cell transplantation beyond first remission.
    Appelbaum FR
    Leukemia; 2002 Feb; 16(2):157-9. PubMed ID: 11840278
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
    Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
    Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
    Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
    Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U
    Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
    Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
    Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.